Thermo Fisher Scientific Launches New CXCL10 Testing Service

Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
torsdag, maj 2, 2024
Information
Tags: 
Research, General Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Science, Surgery, Biotechnology, Medical Supplies, Other Science, Health, Mortality, FDA, Inflammation, Health equity, Risk, Organ transplantation, LDT, Immunosuppression, Collection, CLIA, Thermo Fisher Scientific, Patient, Mental health, CXCL10, Quality of life, Disease, Medical device
Geotags: 
UNITED STATES, NORTH AMERICA, CALIFORNIA
⚠ generated by AI ↴
Sammanfattning
Key Points: 
  • Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests.
  • In keeping with our commitment to health equity, we believe this lower-cost, non-invasive testing option can expand access to care and improve patient adherence, since the sample can be collected at any local clinic,” says Chris McCloskey, director, Transplant Services, Thermo Fisher Scientific.
  • Thermo Fisher’s CXCL10 testing service may supplement current standards of care that may lack specificity or sensitivity, which may lead to unnecessary and invasive biopsies, or produce results too late to influence care, making treating rejection more difficult.
  • The Thermo Fisher One Lambda Laboratories CXCL10 assay was developed and validated by One Lambda Laboratories.


For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant.

Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests. Multiple studies have shown that elevated urinary CXCL10 levels are associated with inflammation and early kidney transplant rejection, as outlined in a recent article in Current Opinion in Organ Transplantation.

“Current methods of post-transplant monitoring can represent a significant financial and physical burden for many transplant patients. In keeping with our commitment to health equity, we believe this lower-cost, non-invasive testing option can expand access to care and improve patient adherence, since the sample can be collected at any local clinic,” says Chris McCloskey, director, Transplant Services, Thermo Fisher Scientific.

Thermo Fisher’s CXCL10 testing service may supplement current standards of care that may lack specificity or sensitivity, which may lead to unnecessary and invasive biopsies, or produce results too late to influence care, making treating rejection more difficult. This can lead to an aggressive immunosuppression regime, increasing patient morbidity and mortality risks.

“We’ve heard directly from patients that invasive biopsies and aggressive immunosuppression to prevent rejection can be incredibly detrimental to their physical and mental health. That’s why we’re proud to be at the forefront of industry, leading the way with new non-invasive tests designed to improve patient outcomes and quality of life throughout the transplant journey,” adds Tina Liedtky, president, Transplant Diagnostics, Thermo Fisher Scientific.

Learn more at Thermo Fisher Scientific One Lambda CXCL10 Testing Services.

The Thermo Fisher One Lambda Laboratories CXCL10 assay was developed and validated by One Lambda Laboratories. This laboratory developed test (LDT) is used for clinical purposes by the CLIA-certified laboratory performing the test. This test has not been cleared or approved by the FDA as an in vitro diagnostic test.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Copyright: 
Copyright Business Wire 2024